Dihydroorotate Dehydrogenase Inhibitor
-
DHODH-IN-21
0 ImagesCat. No.: HY-149030CAS No.: 2450341-39-4DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML).
-
NDs-IN-1
0 ImagesCat. No.: HY-158334CAS No.: 3033806-97-9(Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
-
DHODH-IN-19
0 ImagesCat. No.: HY-144169CAS No.: 2742675-85-8DHODH-IN-19 is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1).
-
hDHODH-IN-12
0 ImagesCat. No.: HY-149877hDHODH-IN-12 is a potent DHODH inhibitor with an IC50 value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer.
-
DHODH-IN-31
0 ImagesCat. No.: HY-178156Purity: 99.55%DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2.
-
Indoluidin D
0 ImagesCat. No.: HY-182550CAS No.: 2763081-61-2Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC50 of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia.
-
hDHODH-IN-7
0 ImagesCat. No.: HY-135667CAS No.: 1644156-41-1DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a human dihydroorotate dehydrogenase inhibitor. DHODH-IN-9 has antiviral effect with a pMIC50 of 7.4.
-
DHODH-IN-22
0 ImagesCat. No.: HY-149031CAS No.: 2450341-75-8DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML).
-
DHODH-IN-26
0 ImagesCat. No.: HY-158023DHODH-IN-26 (compound B2) is a mitochondria-targeting DHODH inhibitor. DHODH-IN-26 shows anticancer activity, triggers the formation of reactive oxygen species (ROS), promots mitochondrial lipid peroxidation, and induces ferroptosis.
-
DHODH-IN-15
0 ImagesCat. No.: HY-135679CAS No.: 1364791-88-7DHODH-IN-15 (Compound 7b) is a hydroxyfurazan analog of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis.
-
Indoluidin E
0 ImagesCat. No.: HY-139825CAS No.: 2763081-76-9Indoluidin E selectively inhibits DHODH and suppresses cancer cell growth.
-
OART
0 ImagesCat. No.: HY-177483Synonyms: Oxaliplatin-artesunateOART (Oxaliplatin-artesunate) is a ferroptosis inducer. OART significantly inhibits tumor cell proliferation. OART induces cytoplasmic and mitochondrial LPO to promote tumor ferroptosis, via destroying glutathione-mediated ferroptosis defense system and enhancing iron-dependent Fenton reaction. OART enhances tumor immunogenicity, transforming tumor environment from immunosuppressive to immunosensitive. OART has strong tumor regression in tumor-bearing mouse models. OART can be used for cancer immunotherapy research.
-
hDHODH-IN-16
0 ImagesCat. No.: HY-168335hDHODH-IN-16 (Compound 3t) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor, with an IC50 of 0.11 μM. hDHODH-IN-16 shows very low cytotoxicity to healthy HaCaT cells, with an IC50 value greater than 200 µM.
-
DHODH-IN-28
0 ImagesCat. No.: HY-174816DHODH-IN-28 (Compound 11a) is a potent fluorescent inhibitor targeting human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 170 nM. DHODH-IN-28 exhibits antileukemic and antiviral activities. DHODH-IN-28 is promising for research of cancers and infectious diseases.
-
DHODH-IN-25
0 ImagesCat. No.: HY-163328CAS No.: 2619531-95-0DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML).
-
DHODH-IN-4
0 ImagesCat. No.: HY-135619CAS No.: 1148125-93-2DHODH-IN-4 (compound 17) is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor, with IC50 values of 4 μM and 0.18 μM for PfDHODH and HsDHODH, respectively. DHODH-IN-4 (compound 17) possess antimalarial activity.
-
hDHODH-IN-9
0 ImagesCat. No.: HY-147788CAS No.: 133676-47-8hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC50 of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases.
-
DHODH-IN-24
0 ImagesCat. No.: HY-163158CAS No.: 418775-30-1DHODH-IN-24 (compound 16) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 91 nM.
-
MEDS700
0 ImagesCat. No.: HY-183336CAS No.: 2770979-81-0MEDS700 is a blood-brain barrier permeable inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 1.5 nM. MEDS700 induces apoptosis and differentiation, and inhibits proliferation of cancer cells. MEDS700 can be used in research on acute myeloid leukemia and other conditions.
